Email Alert RSS
Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui. Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 180-186. DOI: 10.12290/xhyxzz.2021-0764
Citation: LIU Qingxing, CHEN Xiaoyuan, ZHU Zhaohui. Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 180-186. DOI: 10.12290/xhyxzz.2021-0764
shu

Clinical Translational Research of Evans Blue Modified Peptides Used for Theranostics

  • 1.

    Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing International Science and Technology Cooperation Base of Nuclear Medicine Precision Diagnosis and Treatment Technology Innovation, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore 119077

Funds: 

National Natural Science Foundation of China 81871392

The Capital Health Development Scientific Research Project 2018-1-4011

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-016

CAMS Clinical and Translational Medicine Research Fund 2019XK320032

More Information
  • Corresponding author:

    CHEN Xiaoyuan, E-mail: chen.shawn@nus.edu.sg

    ZHU Zhaohui, E-mail: zhuzhh@pumch.cn

  • Received Date: November 30, 2021
  • Accepted Date: December 28, 2021
  • Available Online: January 11, 2022
  • Issue Publish Date: March 29, 2022
    Graphical Abstract
    • Abstract
  • Peptide receptor radionuclide therapy (PRRT) specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells that overexpress specific receptors. In recent years, how to further improve the efficacy of radiotherapeutic drugs for PRRT has been an international research hotspot.The peptides with Evans blue motif, uses endogenous albumin as a reversible carrier to effectively extend the half-life in the blood and substantially increase targeted accumulation and retention within the tumor to achieve better efficacy. This review focuses on the clinical translational research of Evans blue modified peptides used for theranostics.
    • FullText(HTML)
    • References (43)
  • [1]
    Sand KM, Bern M, Nilsen J, et al. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics[J]. Front Immunol, 2014, 5: 682.
    [2]
    Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy[J]. Chem Soc Rev, 2016, 45: 1432-1456. DOI: 10.1039/C5CS00158G
    [3]
    Evans HM, Schulemann W. The Action of Vital Stains Belonging to the Benzidine Group[J]. Science, 1914, 39: 443-454. DOI: 10.1126/science.39.1004.443
    [4]
    Freedman FB, Johnson JA. Equilibrium and kinetic properties of the Evans blue-albumin system[J]. Am J Physiol, 1969, 216: 675-681. DOI: 10.1152/ajplegacy.1969.216.3.675
    [5]
    Niu G, Lang L, Kiesewetter DO, et al. In Vivo Labeling of Serum Albumin for PET[J]. J Nucl Med, 2014, 55: 1150-1156. DOI: 10.2967/jnumed.114.139642
    [6]
    Wang Y, Lang L, Huang P, et al. In vivo albumin labeling and lymphatic imaging[J]. Proc Natl Acad Sci U S A, 2015, 112: 208-213. DOI: 10.1073/pnas.1414821112
    [7]
    Zhang J, Lang L, Zhu Z, et al. Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB[J]. J Nucl Med, 2015, 56: 1609-1614. DOI: 10.2967/jnumed.115.159640
    [8]
    Zang J, Liu Q, Sui H, et al. Combined (68)Ga-NOTA-Evans Blue Lymphoscintigraphy and (68)Ga-NOTA-RM26 PET/CT Evaluation of Sentinel Lymph Node Metastasis in Breast Cancer Patients[J]. Bioconjug Chem, 2020, 31: 396-403. DOI: 10.1021/acs.bioconjchem.9b00789
    [9]
    Long X, Zhang J, Zhang D, et al. Microsurgery guided by sequential preoperative lymphography using (68)Ga-NEB PET and MRI in patients with lower-limb lymphedema[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1501-1510. DOI: 10.1007/s00259-017-3676-6
    [10]
    Zhang W, Wu P, Li F, et al. Potential Applications of Using 68Ga-Evans Blue PET/CT in the Evaluation of Lymphatic Disorder: Preliminary Observations[J]. Clin Nucl Med, 2016, 41: 302-308. DOI: 10.1097/RLU.0000000000001171
    [11]
    Hou G, Jiang Y, Xu W, et al. (68)Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with (99m)TC-ASC lymphoscintigraphy: a prospective study[J]. Orphanet J Rare Dis, 2021, 16: 279. DOI: 10.1186/s13023-021-01895-1
    [12]
    Hou G, Hou B, Jiang Y, et al. 68Ga-NOTA-Evans Blue TOF PET/MR Lymphoscintigraphy Evaluation of the Severity of Lower Limb Lymphedema[J]. Clin Nucl Med, 2019, 44: 439-445. DOI: 10.1097/RLU.0000000000002584
    [13]
    Chen H, Tong X, Lang L, et al. Quantification of Tumor Vascular Permeability and Blood Volume by Positron Emission Tomography[J]. Theranostics, 2017, 7: 2363-2376. DOI: 10.7150/thno.19898
    [14]
    Bombardieri E, Maccauro M, De Deckere E, et al. Nuclear medicine imaging of neuroendocrine tumours[J]. Ann Oncol, 2001, 12 Suppl 2: S51-S61.
    [15]
    Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 66-74. DOI: 10.2967/jnumed.117.202275
    [16]
    Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. DOI: 10.1056/NEJMoa1607427
    [17]
    Tian R, Jacobson O, Niu G, et al. Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy[J]. Theranostics, 2018, 8: 735-745. DOI: 10.7150/thno.23491
    [18]
    Bandara N, Jacobson O, Mpoy C, et al. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent[J]. Bioconjug Chem, 2018, 29: 2448-2454. DOI: 10.1021/acs.bioconjchem.8b00341
    [19]
    Zhang J, Wang H, Jacobson O, et al. Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue (177)Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors[J]. J Nucl Med, 2018, 59: 1699-1705. DOI: 10.2967/jnumed.118.209841
    [20]
    Wang H, Cheng Y, Zhang J, et al. Response to Single Low-dose (177)Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study[J]. Theranostics, 2018, 8: 3308-3316. DOI: 10.7150/thno.25919
    [21]
    Liu Q, Cheng Y, Zang J, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog (177)Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 947-957. DOI: 10.1007/s00259-019-04530-1
    [22]
    Liu Q, Zang J, Sui H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of (177)Lu-DOTA-EB-TATE[J]. J Nucl Med, 2021, 62: 386-392. DOI: 10.2967/jnumed.120.248658
    [23]
    Bergsma H, Konijnenberg MW, Kam BL, et al. Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 453-463. DOI: 10.1007/s00259-015-3193-4
    [24]
    Sabet A, Dautzenberg K, Haslerud T, et al. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 1238-1246. DOI: 10.1007/s00259-015-3041-6
    [25]
    Sabet A, Haslerud T, Pape UF, et al. Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 205-210. DOI: 10.1007/s00259-013-2547-z
    [26]
    Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience[J]. Pancreas, 2014, 43: 518-525. DOI: 10.1097/MPA.0000000000000113
    [27]
    Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors[J]. Eur J Nucl Med Mol Imaging, 2015, 42: 5-19. DOI: 10.1007/s00259-014-2893-5
    [28]
    Paganelli G, Sansovini M, Ambrosetti A, et al. 177Lu-DOTA-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase Ⅱ study[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 1845-1851. DOI: 10.1007/s00259-014-2735-5
    [29]
    Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate[J]. J Nucl Med, 2013, 54: 1857-1861. DOI: 10.2967/jnumed.112.119347
    [30]
    Jonathan S, Edward W, Beth C, et al. NETTER-1 Phase Ⅲ in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results[J]. J Nucl Med, 2016, 57: 629.
    [31]
    Brieau B, Hentic O, Lebtahi R, et al. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy[J]. Endocr Relat Cancer, 2016, 23: L17-L23. DOI: 10.1530/ERC-15-0543
    [32]
    Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues[J]. Clin Cancer Res, 1997, 3: 81-85.
    [33]
    Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression[J]. Hum Pathol, 2007, 38: 696-701. DOI: 10.1016/j.humpath.2006.11.012
    [34]
    Wang W, Tavora F, Sharma R, et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma[J]. Urol Oncol, 2009, 27: 525-528. DOI: 10.1016/j.urolonc.2008.04.007
    [35]
    Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia[J]. Histol Histopathol, 2004, 19: 715-718.
    [36]
    Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies[J]. J Nucl Med, 2015, 56: 1169-1176. DOI: 10.2967/jnumed.115.158550
    [37]
    Benesova M, Schafer M, Bauder-Wust U, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer[J]. J Nucl Med, 2015, 56: 914-920. DOI: 10.2967/jnumed.114.147413
    [38]
    Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. DOI: 10.1056/NEJMoa2107322
    [39]
    Wang Z, Jacobson O, Tian R, et al. Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent (90)Y-DOTA-EB-MCG[J]. Bioconjug Chem, 2018, 29: 2309-2315. DOI: 10.1021/acs.bioconjchem.8b00292
    [40]
    Wang Z, Tian R, Niu G, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors[J]. Bioconjug Chem, 2018, 29: 3213-3221. DOI: 10.1021/acs.bioconjchem.8b00556
    [41]
    Zang J, Fan X, Wang H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 148-158. DOI: 10.1007/s00259-018-4096-y
    [42]
    Zang J, Liu Q, Sui H, et al. (177)Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer[J]. J Nucl Med, 2020, 61: 1772-1778. DOI: 10.2967/jnumed.120.242263
    [43]
    Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19: 825-833. DOI: 10.1016/S1470-2045(18)30198-0
    • Related Articles

  • Related Articles

    [1]ZHANG Xueqin, ZHAO Yun, LIU Jie, GE Long, XING Ying, REN Simeng, WANG Yifei, ZHANG Wenzheng, ZHANG Di, WANG Shihua, SUN Yao, WU Min, FENG Lin, WEN Tiancai. Status of Clinical Practice Guideline Information Platforms[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 462-471. DOI: 10.12290/xhyxzz.2024-0496
    [2]HUANG Lu, WU Youbin, NI Yiran, LIU Mengyuan, WU Jiangfeng, ZHANG Yanqiong. The Mechanism of miRNAs in Liver Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1251-1257. DOI: 10.12290/xhyxzz.2023-0125
    [3]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [4]KONG Weiming, LYU Wenwen, JIANG Jiayuan, FENG Tienan, YU Zhangsheng. Construction and Management of Biobank Information System for Multi-center Colorectal Cancer Clinical Research[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 664-669. DOI: 10.12290/xhyxzz.2021-0763
    [5]Ke ZENG, Yu WANG, Wei-guo ZHU. Information Technology-related Medical Adverse Events[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 196-201. DOI: 10.3969/j.issn.1674-9081.20190083
    [6]Dan GUO, Wen-hang YANG, Ying-chun XU. Construction and Development of the Information System of Clinical Biobank[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(1): 81-86. DOI: 10.3969/j.issn.1674-9081.2018.01.015
    [7]Xiao-yun ZHANG, Jian-yu HAO. PTEN and Digestive Organ Fibrosis[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 300-304. DOI: 10.3969/j.issn.1674-9081.2017.05.020
    [10]Ji-hai LIU, Lian-jun ZHAO, Wan-peng LIAO, Xue-zhong YU, Shu-bin GUO, Teng-da XU, Wen-hua ZHOU, Hua-dong ZHU. Design and Implementation of Emergency Information System Based on Cognitive Task Analysis[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(3): 224-232. DOI: 10.3969/j.issn.1674-9081.2013.03.002

  • Cited by

    Periodical cited type(4)

    1. 杨颖熙，徐洪智. 遗传算法在智能排班中的应用研究. 福建电脑. 2025(02): 30-34 .
    2. 林惠燕，缪羽，王慧灵，祝美术，冷英杰. 智能云平台在医院护理人员管理中的应用. 医疗装备. 2023(01): 122-125 .
    3. 林珂珂，顾雨极，柳云飞，周姣，李敏. 适用于中小微企业的智能排班系统. 科学技术创新. 2023(13): 96-99 .
    4. 夏天舒，李宇豪，宣明辉，林新雨. 基于遗传算法的银行智能排班系统设计. 现代信息科技. 2023(12): 128-132+136 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (741) PDF downloads (108) Cited by(6)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close